We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Primary Care

Journal Scan / Research · May 08, 2022

Levothyroxine in Euthyroid Peroxidase Antibody–Positive Women With Recurrent Pregnancy Loss

The Lancet Diabetes & Endocrinology

 

Additional Info

The Lancet Diabetes & Endocrinology
Levothyroxine in euthyroid thyroid peroxidase antibody positive women with recurrent pregnancy loss (T4LIFE trial): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Lancet Diabetes Endocrinol 2022 May 01;10(5)322-329, MM van Dijk, R Vissenberg, E Fliers, JAM van der Post, MP van der Hoorn, S de Weerd, WK Kuchenbecker, A Hoek, JM Sikkema, HR Verhoeve, KA Broeze, CH de Koning, W Verpoest, OB Christiansen, C Koks, JP de Bruin, DNM Papatsonis, H Torrance, M van Wely, PH Bisschop, M Goddijn

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading